Optimal Screening Strategy for Bladder Cancer in at Risk Patients

What this Trial Is About

Bladder cancer is a common cancer, especially among men over 50, often caused by smoking and detected late due to few early symptoms. This research aims to evaluate whether routine urine screening every six months for two years can help detect bladder cancer earlier in high-risk patients, such as those with significant smoking history or certain occupational exposures. The study is a single-arm trial comparing results to historical data from standard care. Participants will undergo urinalysis testing every six months for two years. Depending on red blood cell counts in the urine, participants may receive further screening with cystoscopy and upper tract imaging or urine marker testing with Cxbladder triage plus imaging. Those with suspicious findings will receive treatment as per standard practice. This approach is compared to historical controls from SEER registries where bladder cancer was detected by usual care. During the study, patients will complete urine tests bi-annually and may undergo additional procedures based on test results. Researchers will track bladder cancer incidence over five years and secondary outcomes like smoking cessation and screening intervals. The study includes follow-up assessments and monitoring for up to two years to evaluate the effectiveness of this screening approach compared to historical outcomes.

Bladder Cancer Screening Trial